LLY vs DGX
By Alex · Tickerpine
Eli Lilly and Company vs Quest Diagnostics Incorporated, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | DGX |
|---|---|---|
| Price | $1,220.28 | $237.77 |
| Market cap | $1.09T | $26.24B |
| P/E ratio | 41.0 | 25.2 |
| ROE | 102.29% | 14.60% |
| Profit margin | 33.53% | 9.19% |
| Revenue growth | 47.70% | 10.20% |
| Dividend yield | 0.57% | 1.45% |
| Beta | 0.51 | 0.55 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs DGX in plain English
- LLY is the bigger company — about 41.5× the market cap of DGX.
- DGX is cheaper on earnings (P/E 25.2 vs 41.0).
- LLY earns a higher return on equity (102% vs 15%).
- LLY is growing revenue faster (48% vs 10%).
- DGX has the higher dividend yield (1.45% vs 0.57%).
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
DGX return calculator
See what $1,000 in Quest Diagnostics Incorporated would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.